Selim M. Arcasoy, MD, MPH
Overview
Dr. Arcasoy was recruited to Columbia University as the Medical Program Director of Lung Transplantation in 2001 from the University of Pennsylvania. After his recruitment, he completely turned around the Lung Transplantation Program to rank amongst the top 5 to 10 programs in the country with regard to volume and patient survival. Under his leadership, the Lung Transplant Program has been performing more than 80 transplants annually. In October 2019, Dr. Arcasoy and his team celebrated their 1000th lung transplant since 2001. Despite high transplant volumes and very sick pretransplant candidates, the survival of lung transplant recipients has remained stellar. Currently, 1-year survival of lung transplant recipients at Columbia University is 90%, 5-year survival 65%, and 10-year survival 42%.
Dr. Arcasoy has gained national and international reputation with various leadership roles in professional organizations and scientific societies. He previously chaired the Thoracic Organ Transplant Committee of the AST and the Transplant Network Steering Committee of the ACCP. He recently served in the Thoracic Organ Transplant Committee of the OPTN to develop Continuous Distribution of Lungs. He is currently the Associate Chair for Advanced Lung Failure and Transplantation in the Standards and Guidelines Committee of the ISHLT.
Areas of Expertise / Conditions Treated
- Chronic Lung Disease
- Chronic Obstruct Pulm Disease/COPD
- Emphysema
- General Pulmonology
- Hypersensitivity Pneumonitis
- Idiopathic Pulmonary Fibrosis
- Lung Transplant
- Pulmonary Critical Care Medicine
- Pulmonary Disease
- Pulmonary Fibrosis
- Pulmonary Medicine
- Respiratory Failure
- Restrictive Lung Diseases
- Transplant Pulmonology
Academic Appointments
- Dickinson W. Richards, Jr. Professor of Medicine (in Pediatrics) at CUMC
Administrative Titles
- Medical Program Director, Lung Transplant Program
- Clinical Chief, Division of Pulmonary, Allergy & Critical Care
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian Morgan Stanley Children's Hospital
Languages
- Turkish
Gender
- Male
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- NYP Employee Plan
- NY Signature
- POS
- Student Health
Affinity Health Plan
- Medicaid Managed Care
AgeWell
- Medicare Managed Care
- Special Needs
Amerigroup of New Jersey
- New Jersey Services (Medicaid Managed Care)
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
Fidelis Care
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Quality Health Management
- Quality Health Management
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- SelectHealth
- Special Needs
WellCare
- Medicare Managed Care
- New Jersey Services (Medicaid Managed Care)
- New Jersey Services (Medicare Managed Care)
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- MD, Ege University Medical School, Turkey
- MPH, Columbia University Mailman School of Public Health
- Internship: 1993 State University of New York Health Science Center at Brooklyn
- Residency: 1994 State University of New York Health Science Center at Brooklyn
- Fellowship: 1997 The University of Pittsburgh Medical Center
Board Certifications
- Critical Care Medicine
- Internal Medicine
- Pulmonary Disease
Honors & Awards
- 2016: Fellow of the American Society of Transplantation (F.A.S.T.)
- 2002-21: Inclusion in America’s Top Doctors and Top Doctors: New York Metro Area
- 2009-21: Inclusion in New York City Super Doctors, New York Times Magazine
- 2002: Fellow of the American College of Physicians (F.A.C.P.)
- 2001: Fellow of the American College of Chest Physicians (F.C.C.P.)
- 1999: Rank Valedictorian of class in Ege University School of Medicine
- 1984: Rank Valedictorian of class in Tarsus American College
Research
Advanced lung disease and lung transplantation
Research Interests
- Co-morbidities in advanced pulmonary disease
- Collaborative investigation in immune tolerance
- Idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis
- Lung volume reduction for emphysema
- Novel immunosuppressive regimens and antimicrobial therapies in lung transplantation
- Outcomes of patients with advanced lung disease before and after transplantation
- Patient selection and outcomes on the waiting list for lung transplantation
- Post-transplant complications
- Predictors and diagnosis of acute and chronic lung rejection
- Pulmonary embolism and thrombolytic therapy
- Studies of genetic testing for diagnosis of organ rejection
Grants
Principal investigator: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow Device plus Standard of Care versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post-Single Lung Transplantation. Protocol No: BT-LCsA-301-SLT
Sponsor: BREATH Therapeutics Inc.
New York-Presbyterian Hospital, Columbia University College of Physicians and Surgeons
Principal investigator: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow Device plus Standard of Care versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation. Protocol No: BT-LCsA-302-DLT
Sponsor: BREATH Therapeutics Inc.
New York-Presbyterian Hospital, Columbia University College of Physicians and Surgeons
Principal investigator: A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow Device plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Single or Double Lung Transplantation. Protocol No: BT-LCsA-303-FU (BOSTON-3)
Sponsor: BREATH Therapeutics Inc.
New York-Presbyterian Hospital, Columbia University College of Physicians and Surgeons
Principal investigator: Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts (CAG-00324R2).
Sponsor: Center for Medicare and Medicaid Services and Therakos
New York-Presbyterian Hospital, Columbia University College of Physicians and Surgeons
Selected Publications
- A.M. Layton, H.F. Armstrong, H.P. Kim, K.S. Meza, F. D’Ovidio, S.M. Arcasoy. Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med 2017; 126: 59-67.
- J.M. Diamond, S. Arcasoy, C.C. Kennedy, M. Eberlein, J.P. Singer, G.M. Patterson, J.D. Edelman, G. Dhillon, T. Pena, S.M. Kawut, J.C. Lee, R. Girgis, J. Dark, G. Thabut. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017 Oct;36(10):1104-1113.
- L.J. Benvenuto, D.R. Anderson, H.P. Kim, J.L. Hook, L. Shah, H.Y. Robbins, F. D’Ovidio, M. Bacchetta, J.R. Sonett, S.M. Arcasoy. Geographic disparities in donor lung supply and lung transplant waitlist outcomes: A Cohort Study. Am J Transplant; 2018; 18:1471-80
- L.J. Benvenuto, M.R. Anderson, S.M. Arcasoy. New frontiers in immunosuppression. J Thorac Dis 2018;10(5):3141-55.
- M. Aversa, L. Benvenuto, H. Kim, L. Shah, H. Robbins, B.P. Stanifer, F. D'Ovidio, E.R. Vasilescu, J. Sonett, S.M. Arcasoy. Effect of Calculated Panel Reactive Antibody Value on Waitlist Outcomes for Lung Transplant Candidates. Ann Transplant 2019 Jun 28;24:383-392.
- D. Rudym, L. Benvenuto, J. Costa, M. Aversa, H. Robbins, L. Shah, H. Kim, B.P. Stanifer, J. Sonett, F. D’Ovidio, S.M. Arcasoy. What Awaits on the Other Side: Post-Lung Transplant Morbidity and Mortality After Pre-Transplant Hospitalization. Ann Transplant 2020;25:e922641.
- M. Aversa, L. Benvenuto, M. Anderson, L. Shah, H. Robbins, M. Pereira, J. Scheffert, M. Carroll, J. Hum, M. Nolan, G. Reilly, P. Lemaitre, B.P. Stanifer, F. D’Ovidio, J. Sonett, S. Arcasoy. Covid-19 in lung transplant recipients: A single center case series from New York City. Am J Transplant 2020; 20:3072-80.
For a complete list of publications, please visit PubMed.gov